Stocks and Investing Stocks and Investing
Wed, January 26, 2022

Tazeen Ahmad Maintained (SRPT) at Strong Buy with Decreased Target to $105 on, Jan 26th, 2022


Published on 2024-10-27 19:25:56 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $122 to $105 on, Jan 26th, 2022.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Tazeen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $92 on, Tuesday, January 18th, 2022
  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021


These are the ratings of the 5 analyists that currently disagree with Tazeen


  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $150 on, Wednesday, January 5th, 2022
  • Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $125 on, Thursday, December 9th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $130 on, Friday, November 5th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $145 on, Thursday, November 4th, 2021
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021

Contributing Sources